Business Description
CSPC Pharmaceutical Group Ltd
ISIN : US12591J2078
Share Class Description:
CSPCY: ADRTotal Employee Number:
19,700Compare
Compare
Traded in other countries / regions
01093.Hong KongCVG.GermanyCHJTF.USA1093N.Mexico IPO Date
2018-04-03Description
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.83 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.11 | |||||
Interest Coverage | 85.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.49 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.6 | |||||
3-Year EBITDA Growth Rate | -9.3 | |||||
3-Year EPS without NRI Growth Rate | -14.8 | |||||
3-Year FCF Growth Rate | -9.3 | |||||
3-Year Book Growth Rate | 4.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.08 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.27 | |||||
9-Day RSI | 52.67 | |||||
14-Day RSI | 47.75 | |||||
3-1 Month Momentum % | -19.48 | |||||
6-1 Month Momentum % | -14.29 | |||||
12-1 Month Momentum % | -4.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.19 | |||||
Quick Ratio | 1.88 | |||||
Cash Ratio | 0.87 | |||||
Days Inventory | 123.15 | |||||
Days Sales Outstanding | 74.18 | |||||
Days Payable | 106.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.15 | |||||
Dividend Payout Ratio | 0.83 | |||||
3-Year Dividend Growth Rate | 7.4 | |||||
Forward Dividend Yield % | 4.15 | |||||
5-Year Yield-on-Cost % | 6.81 | |||||
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 4.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.3 | |||||
Operating Margin % | 14.32 | |||||
Net Margin % | 12.81 | |||||
EBITDA Margin % | 21.99 | |||||
FCF Margin % | 13.98 | |||||
OCF Margin % | 22.96 | |||||
ROE % | 10.08 | |||||
ROA % | 7.25 | |||||
ROIC % | 10.34 | |||||
3-Year ROIIC % | -26.05 | |||||
ROC (Joel Greenblatt) % | 31.32 | |||||
ROCE % | 11.91 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.02 | |||||
Forward PE Ratio | 10.51 | |||||
PE Ratio without NRI | 23.9 | |||||
Shiller PE Ratio | 17.27 | |||||
Price-to-Owner-Earnings | 15.51 | |||||
PS Ratio | 2.83 | |||||
PB Ratio | 2.17 | |||||
Price-to-Tangible-Book | 2.39 | |||||
Price-to-Free-Cash-Flow | 20.35 | |||||
Price-to-Operating-Cash-Flow | 12.38 | |||||
EV-to-EBIT | 15.88 | |||||
EV-to-Forward-EBIT | 4.58 | |||||
EV-to-EBITDA | 11.88 | |||||
EV-to-Forward-EBITDA | 2.93 | |||||
EV-to-Revenue | 2.61 | |||||
EV-to-Forward-Revenue | 1.75 | |||||
EV-to-FCF | 18.76 | |||||
Price-to-GF-Value | 1.06 | |||||
Price-to-Projected-FCF | 1.25 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Graham-Number | 1.48 | |||||
| Price-to-Net-Current-Asset-Value | 8.15 | |||||
Earnings Yield (Greenblatt) % | 6.3 | |||||
FCF Yield % | 4.93 | |||||
Forward Rate of Return (Yacktman) % | 0.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CSPCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CSPC Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,606.907 | ||
| EPS (TTM) ($) | 0.162 | ||
| Beta | -0.1215 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.28 | ||
| Volatility % | 40.39 | ||
| 14-Day RSI | 47.75 | ||
| 14-Day ATR ($) | 0.141951 | ||
| 20-Day SMA ($) | 3.5761 | ||
| 12-1 Month Momentum % | -4.82 | ||
| 52-Week Range ($) | 3.26 - 5.83 | ||
| Shares Outstanding (Mil) | 2,851.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CSPC Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CSPC Pharmaceutical Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-21 | In 52 days | ||
| USD 0.076734 Cash Dividend | 2026-06-25 | 3.49 (-1.02%) | ||
| General meeting for 2025 | 2026-05-28 10:00 | 3.53 (-1.75%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 3.73 (-1.84%) | ||
| Annual report for 2025 | 2026-04-28 | 4.54 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 4.17 (-2.23%) | ||
| USD 0.071848 Cash Dividend | 2025-10-20 | 4.67 (+5.66%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 5.32 (-1.57%) | ||
| USD 0.050909 Cash Dividend | 2025-06-05 | 3.79 (+0.00%) | ||
| General meeting for 2024 | 2025-05-30 10:00 | 3.72 (-0.80%) |
Show
Entries
CSPC Pharmaceutical Group Ltd Frequently Asked Questions
What is CSPC Pharmaceutical Group Ltd(CSPCY)'s stock price today?
The current price of CSPCY is $3.58. The 52 week high of CSPCY is $5.83 and 52 week low is $3.26.
When is next earnings date of CSPC Pharmaceutical Group Ltd(CSPCY)?
The next earnings date of CSPC Pharmaceutical Group Ltd(CSPCY) is 2026-08-21 Est..
Does CSPC Pharmaceutical Group Ltd(CSPCY) pay dividends? If so, how much?
The Dividend Yield %  of CSPC Pharmaceutical Group Ltd(CSPCY) is 4.15% (As of Today), Highest Dividend Payout Ratio of CSPC Pharmaceutical Group Ltd(CSPCY) was 0.83. The lowest was 0. And the median was 0.29. The  Forward Dividend Yield % of CSPC Pharmaceutical Group Ltd(CSPCY) is 4.15%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:CSPCY
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on CSPC Pharmaceutical Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers